Mark Rus, Delix CEO
A new psychedelics player emerges to treat mental health disorders — minus the hallucinogenic effects
One line in an academic paper changed everything for David Olson.
It was 2018 when Olson’s lab at the University of California, Davis published a paper demonstrating psychedelics’ ability to promote neuroplasticity. Psychedelics research has slowly emerged from the shadows in the last couple decades, with the FDA approving the first psychedelic drug, esketamine, to treat depression in 2019. A handful of companies are now testing the effects of other compounds like psilocybin — the psychoactive ingredient in magic mushrooms — on a suite of mental health disorders.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters